Our latest SOS for CNS

The CNS Company Consultant pens a peer reviewed article on orphan drug designations. Jun 2015

CNS Company consultant Susan McGoldrick chosen as a masterclass leader at SMi Group masterclass event. Jan 2015

The challenges for CNS Clinical Trials, why are there so many failed studies? An article from our CNS Project Director. Jan 2015

Assessment of outcome in mild Alzheimer’s disease.
Jun 2014

CNS – Still Sending Out the SOS?
May 2014

Developing new treatments for MND/ALS – current issues.
Feb 2014

Developing new treatments for Alzheimer’s disease – current issues.
Jan 2014

see previous articles

Neurology & Psychiatry

The CNS Company is an international, niche Clinical Research Organisation (CRO) specialising in neurology, psychiatry and orphan indications

Through our unique approach we can deliver patient recruitment to our clients in these notoriously difficult areas. TCNSC will get you to Last Patient In in as timely a manner as we got you to the First.

Patient Recruitment

TCNSC are the world's first CRO to deliver 437 patients in less than 12 months for a phase III clinical trial in an orphan indication.

We achieve these amazing results through our:
• specialisation in the field of CNS
• a robust and reliable network of clinicians, some of whom we have been working with for over 15 years
• optimising the clinical trial design to balance the needs of the regulatory bodies, the investigators and the patients.

Investigator Relationships

It is the close relationship with our experienced investigators and our scientific expertise, that takes us beyond the patient recruitment phase to also achieving outstanding patient retention.

TCNSC is recognised internationally as experts in conducting proof of concept and pivotal phase II and III trials.



 Follow us:         Contact us: